Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16423307 | 0.86 | RORC (0.42) | OPRK1OPRD1OPRM1RORCAKR1B10 | |
| SCHEMBL556661 | 0.83 | RORC (0.40) | OPRK1OPRD1OPRM1RORCAKR1B10 | |
| SCHEMBL535108 | 0.82 | OPRD1 (0.37) | OPRK1OPRD1OPRM1RORCAKR1B10 | |
| SCHEMBL533916 | 0.81 | RORC (0.39) | OPRK1OPRD1OPRM1RORCAKR1B10 | |
| SCHEMBL533915 | 0.81 | RORC (0.39) | OPRK1OPRD1OPRM1RORCAKR1B10 | |
| SCHEMBL28063989 | 0.79 | OPRK1 (0.56) | OPRK1OPRD1OPRM1 | |
| SCHEMBL16422928 | 0.78 | RORC (0.39) | OPRK1OPRD1OPRM1RORCAKR1B10 | |
| SCHEMBL6042866 | 0.78 | OPRK1 (0.45) | OPRK1OPRD1 | |
| SCHEMBL5379982 | 0.77 | AKR1B10 (0.47) | OPRK1OPRD1OPRM1RORCAKR1B10 | |
| SCHEMBL556118 | 0.77 | OPRD1 (0.41) | OPRK1OPRD1OPRM1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | OPRK1 980/4885OPRD1 1410/4885OPRM1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.